Trellis Vitality: August 2026 Investigation and Current Review

Trellis Vitality now has a graded review: 73.4/100, grade C. Read the current Trellis Vitality scorecard for the six factor scores and the full caveats.

Current provider record

Semaglutide: $150/mo (flat at every dose). Tirzepatide: $199/mo (flat at every dose).

Coverage recorded in the graded review: All 50 states claimed (at least Connecticut, Ohio and South Carolina excluded). The provider record's merchant-verification date is 2026-09-01. This article was reconciled with that existing record on October 6, 2026; this is not a new merchant verification. The August findings below do not establish today's checkout price or resolve every previously documented discrepancy.

The current review records these caveats: An “all 50 states” banner sits on every page while the program's own FAQ says it is suppressed in Connecticut, Ohio and South Carolina at minimum, with no list of the rest. The Terms accepted at intake are unedited platform boilerplate: they name a professional entity the site never mentions, twenty-five times, and impose a membership fee the marketing site says does not exist.

Historical investigation — August 7, 2026

The following investigation records what our August pass found. Its prices, availability, named providers and policies describe that pass, not current offers. Each section is dated to keep those historical observations separate from the current record above. The original citations remain attached to the observations they supported.

Most telehealth sellers publish a number and hope you do not ask what it is a number for. Trellis Vitality (trellisvitality.com) publishes an actual table — molecule down the side, plan length across the top, the month-to-month column labeled as such. Of the seven companies we checked in August 2026 it has the best-formed GLP-1 price surface, and it also has four other programs where the same company falls back to a bare "starting at". This page is the working file on both halves. This was a price-and-disclosure investigation. The later graded review applies the six dimensions in our methodology.

August 2026: The GLP-1 table, which is the good part

Semaglutide is $150 a month on a one-month plan, $140 a month on three months and $133 a month on six. Tirzepatide is $199, $189 and $179 across the same three plan lengths. The table is labeled per-month, longer plans cost less per month, and all dosages are the same price.

Three things about that are unusual enough to name. The one-month column is explicitly the month-to-month rung, so there is no prepay figure masquerading as a monthly rate — the single most common capture error on a cost ranking, and the reason what compounded GLP-1 costs per month spends most of its length on normalization. Dosage does not change the price, so the number you read at 0.25 mg is the number you pay at maintenance. And the discount for committing is about 10 to 11 percent — 11.3 percent on semaglutide, 10.1 percent on tirzepatide — which is a real discount rather than a lock-in dressed as one.

At $150 month-to-month, Trellis is the second-cheapest standard month-to-month semaglutide rung of the seven, behind Pepti at $99 — and unlike Pepti's, this figure did not have a contradictory second ladder sitting behind it.

August 2026: The part with no ladder behind it

Trellis also sells NAD+, glutathione, a Lipo-MIC and B12 injection, and tesamorelin. For all four, the site publishes a single "starting at" figure and nothing else: from $129 a month for NAD+, from $93 for glutathione, from $130 for Lipo-MIC with B12, from $299 for tesamorelin.

Those are not monthly prices and we will not file them as monthly prices. A "starting at" figure with no rung table behind it is an entry point, and on the one program where Trellis does show its rungs, the entry point is the six-month prepay rate roughly 11 percent below the month-to-month one. It is reasonable to suspect the same shape applies here. It is not verified, we could not verify it — the product pages, the build's own scripts and the intake flow all carry no rung table — and a suspicion is not a price. The honest form of any of these on a ranking is "from $129 a month, full ladder not published", and anything shorter overstates what the company has disclosed.

August 2026: A claim the site makes about itself that is not true

Trellis's own blog states, twice, that the company publishes its complete pricing on the program page. It does not. The GLP-1 program page does. The other four publish one figure each with no ladder.

That is a small thing that we would nonetheless mark down, because transparency claims are the easiest kind of claim to check and the most expensive kind to get wrong. The same page carries a set of marketing statistics — a star rating, a current-patient count, an average-time-saved figure and an average-annual-savings figure — none of which is sourced anywhere on the site. We are not reprinting them. An unsourced number that travels into a comparison article becomes a fact about the market that nobody ever measured, and this site's editorial policy exists partly to stop that.

August 2026: Who prescribes, and who fills

The medical group is Arora Health & Aesthetics, LLC, with Dr. Sean Arora as medical director. His NPI, 1841729449, resolves to an active Family Medicine record in the national registry. The dispensing pharmacy is VialsRX, a state-licensed compounding pharmacy in Houston, Texas, named directly in the site's own machine-readable summary file.

Naming the pharmacy is worth more credit than it usually gets. Most of this cohort says "our pharmacy partner" and stops, which leaves the fulfillment dimension with nothing to score and the reader with no way to check anything — see is compounded semaglutide legit and safe? for what that check would even consist of.

The caveat, and it is a real one: The Edit runs on the same medical group and the same medical director. Different pharmacy, different price ladder, separable products — but if both are on your shortlist, you are shortlisting one clinical organization twice. No ranking on this site will present them as independent alternatives, and neither should a reader.

August 2026: Terms, and a thin legal shelf

Trellis states there is no membership fee and no consultation cost, and the assessment is free. We could not corroborate any of that in a terms document, because the terms page is about three kilobytes of text and does not name a legal entity at all. Every other company in this pass names an operator somewhere, even when the address turns out to be a registered-agent suite. All 50 states are claimed, on the strength of a badge and a machine-readable file rather than a published state list.

That combination — a good price surface on the flagship product, a thin legal surface underneath it — was a limitation of the August investigation. Contract terms and clinical oversight account for 28 percent of the rubric; the later scorecard records the evidence and caveats used for its scores.

August 2026: The regulatory screen

The FDA's live warning-letter index returned no company-column match in August 2026 for Trellis Vitality, for its medical group, or for VialsRX. The same pass correctly returned a known February 2026 letter for an unrelated telehealth seller used as a positive control, so those zeros are evidence rather than a query that silently broke. That is the only way an absence is worth reporting.

August 2026: Where it sits

The August GLP-1 table provided useful inputs for the six-point checklist. Trellis now appears in the graded roster; use its current review for the later assessment. Outside GLP-1, treat every published figure as a starting point that has not been shown to be a monthly rate. And if you are still deciding between a compounded program like this one and the branded product it substitutes for, start with compounded vs. brand-name GLP-1 before the price comparison, not after it.